PE20121469A1 - Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa - Google Patents

Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa

Info

Publication number
PE20121469A1
PE20121469A1 PE2012000630A PE2012000630A PE20121469A1 PE 20121469 A1 PE20121469 A1 PE 20121469A1 PE 2012000630 A PE2012000630 A PE 2012000630A PE 2012000630 A PE2012000630 A PE 2012000630A PE 20121469 A1 PE20121469 A1 PE 20121469A1
Authority
PE
Peru
Prior art keywords
indazol
alkyl
piperidin
carbonyl
coa carboxylase
Prior art date
Application number
PE2012000630A
Other languages
English (en)
Inventor
Scott William Bagley
David Andrew Griffith
Daniel Wei-Shung Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20121469A1 publication Critical patent/PE20121469A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE PIRAZOLOESPIROCETONA DE FORMULA (I) DONDE: R1 ES ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO, CICLOALQUILO C3-7, TETRAHIDROFURANILO U OXETANILO; R2 ES H, HALO, ALQUILO C1-3 O CIANO; R3 ES H O ALQUILO C1-3; R4 ES ARILO C6-10, HETEROARILO C5-12 O ARILO HETROCICLICLO CONDENSADO C8-12, CADA UNO OPCIONALMENTE SUSTITUIDO CON UNO A TRES SUSTITUYENTES SELECCIONADOS ENTRE ALQUILO C1-3, ALCOXI C1-3, HALO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-ISOPROPIL-1'-(2-METIL-1H-BENZO[d]IMIDAZOL-6-CARBONIL)-4,6-DIHIDROESPIRO[INDAZOL-5,4'-PIPERIDIN]-7(1H)-ONA; 1-ISOPROPIL-1'-(1H-PIRROLO[3,2-b]PIRIDIN-6-CARBONIL)-4,6-DIHIDROESPIRO[INDAZOL-5,4'-PIPERIDIN]-7(1H)-ONA; 1'-(1H-INDAZOL-5-CARBONIL)-1-ISOPROPIL-6-METIL-4,6-DIHIDROESPIRO[INDAZOL-5,4'-PIPERIDIN]-7(1H)-ONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR DE ACETIL CoA CARBOXILASA SIENDO UTIL EN EL TRATAMIENTO DE DIABETES TIPO II, NEUROPATIA DIABETICA, HIPERTENSION, OBESIDAD
PE2012000630A 2009-11-10 2010-10-29 Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa PE20121469A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10

Publications (1)

Publication Number Publication Date
PE20121469A1 true PE20121469A1 (es) 2012-11-01

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000630A PE20121469A1 (es) 2009-11-10 2010-10-29 Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa

Country Status (39)

Country Link
US (4) US8288405B2 (es)
EP (3) EP2499139B1 (es)
JP (1) JP5114610B1 (es)
KR (2) KR101478517B1 (es)
CN (1) CN102695708B (es)
AP (1) AP3283A (es)
AR (1) AR078944A1 (es)
AU (1) AU2010317501B2 (es)
BR (1) BR112012011072A2 (es)
CA (1) CA2778886C (es)
CL (1) CL2012000999A1 (es)
CO (1) CO6541569A2 (es)
CR (1) CR20120190A (es)
CU (1) CU24077B1 (es)
DK (1) DK2499139T3 (es)
DO (1) DOP2012000128A (es)
EA (1) EA020153B1 (es)
EC (1) ECSP12011880A (es)
ES (1) ES2444543T3 (es)
GE (1) GEP20146169B (es)
HK (1) HK1173724A1 (es)
HN (1) HN2012000973A (es)
HR (1) HRP20140025T1 (es)
IL (1) IL219373A (es)
MA (1) MA33734B1 (es)
MX (1) MX2012005429A (es)
NI (1) NI201200089A (es)
NZ (1) NZ599815A (es)
PE (1) PE20121469A1 (es)
PL (1) PL2499139T3 (es)
PT (1) PT2499139E (es)
RS (1) RS53156B (es)
SI (1) SI2499139T1 (es)
TN (1) TN2012000192A1 (es)
TW (1) TWI394756B (es)
UA (1) UA102336C2 (es)
UY (1) UY33020A (es)
WO (1) WO2011058474A1 (es)
ZA (1) ZA201204231B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
ES2444543T3 (es) 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
CN103189377B (zh) 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
PT2699576E (pt) 2011-04-22 2016-03-09 Pfizer Derivados de pirazoloespirocetona para utilização como inibidores de acetil-coa carboxilase
KR102371532B1 (ko) 2011-09-02 2022-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
KR20160042089A (ko) 2013-09-12 2016-04-18 화이자 인코포레이티드 심상성 여드름 치료용 아세틸-CoA 카복실라아제 억제제의 용도
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6660060B2 (ja) 2014-09-16 2020-03-04 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
WO2016044138A1 (en) * 2014-09-17 2016-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US10889903B2 (en) 2014-11-10 2021-01-12 National University Corporation Yokohama National University Oxygen-generating anode
NZ734993A (en) 2015-02-27 2024-03-22 Incyte Holdings Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
JP7142375B2 (ja) 2017-06-30 2022-09-27 クイクスゲン インコーポレイテッド 新規なスピロラクトン化合物及び医薬組成物
EP3713942B8 (en) 2017-11-21 2023-04-12 Pfizer Inc. Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
AU2021275292A1 (en) 2020-05-21 2022-12-15 Shionogi & Co., Ltd. Pharmaceutical for treating fatty liver diseases
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60301491T2 (de) 2002-02-27 2006-05-18 Pfizer Products Inc., Groton Acc-hemmer
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
ATE509023T1 (de) 2005-07-19 2011-05-15 Merck Sharp & Dohme Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer
JPWO2007013691A1 (ja) * 2005-07-29 2009-02-12 武田薬品工業株式会社 スピロ環化合物
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
EP1951251B1 (en) 2005-11-18 2010-12-29 Merck Sharp & Dohme Corp. Spirohydantoin aryl cgrp receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
MX2009005604A (es) * 2006-11-29 2009-06-08 Pfizer Prod Inc Inhibidores espiro cetona de acetil-coa carboxilasa.
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
JPWO2008102749A1 (ja) 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
CA2683695C (en) * 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
US20100211592A1 (en) * 2007-07-20 2010-08-19 Mark Jonathon Brownlee Email response time expectation system
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2009144554A1 (en) * 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
JP2011521940A (ja) * 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
US8524730B2 (en) 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
AU2009271634A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
US8524733B2 (en) * 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2778316A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
ES2444543T3 (es) 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
PT2621493T (pt) * 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
PT2699576E (pt) * 2011-04-22 2016-03-09 Pfizer Derivados de pirazoloespirocetona para utilização como inibidores de acetil-coa carboxilase

Also Published As

Publication number Publication date
RS53156B (en) 2014-06-30
IL219373A (en) 2014-04-30
US8288405B2 (en) 2012-10-16
US20130030181A1 (en) 2013-01-31
CO6541569A2 (es) 2012-10-16
CL2012000999A1 (es) 2012-07-20
NI201200089A (es) 2012-08-20
IL219373A0 (en) 2012-06-28
ZA201204231B (en) 2013-02-27
CN102695708B (zh) 2014-10-15
CA2778886A1 (en) 2011-05-19
ECSP12011880A (es) 2012-07-31
KR101550557B1 (ko) 2015-09-04
HRP20140025T1 (hr) 2014-02-14
AU2010317501A1 (en) 2012-05-17
NZ599815A (en) 2013-04-26
PL2499139T3 (pl) 2014-04-30
GEP20146169B (en) 2014-09-25
DOP2012000128A (es) 2012-08-31
CA2778886C (en) 2014-01-07
US20110111046A1 (en) 2011-05-12
WO2011058474A1 (en) 2011-05-19
TW201127838A (en) 2011-08-16
EA201290191A1 (ru) 2012-12-28
MA33734B1 (fr) 2012-11-01
BR112012011072A2 (pt) 2017-06-20
DK2499139T3 (da) 2014-01-27
CU20120071A7 (es) 2013-05-31
ES2444543T3 (es) 2014-02-25
EP2499139B1 (en) 2013-12-11
MX2012005429A (es) 2012-06-19
EP2499139A1 (en) 2012-09-19
HN2012000973A (es) 2015-03-02
UA102336C2 (uk) 2013-06-25
US20130296319A1 (en) 2013-11-07
CN102695708A (zh) 2012-09-26
PT2499139E (pt) 2014-02-10
EP2947082A1 (en) 2015-11-25
CR20120190A (es) 2012-05-24
EA020153B1 (ru) 2014-09-30
SI2499139T1 (sl) 2014-01-31
AP3283A (en) 2015-05-31
US8507681B2 (en) 2013-08-13
KR20140034919A (ko) 2014-03-20
KR101478517B1 (ko) 2015-01-02
EP2676958A1 (en) 2013-12-25
US20140288111A1 (en) 2014-09-25
US8802690B2 (en) 2014-08-12
AU2010317501B2 (en) 2013-06-06
AR078944A1 (es) 2011-12-14
JP5114610B1 (ja) 2013-01-09
TN2012000192A1 (fr) 2013-12-12
US9139587B2 (en) 2015-09-22
EP2676958B1 (en) 2015-07-01
WO2011058474A8 (en) 2012-04-26
UY33020A (es) 2011-06-30
HK1173724A1 (en) 2013-05-24
JP2013510192A (ja) 2013-03-21
KR20120099460A (ko) 2012-09-10
CU24077B1 (es) 2015-03-30
TWI394756B (zh) 2013-05-01
AP2012006269A0 (en) 2012-06-30

Similar Documents

Publication Publication Date Title
PE20121469A1 (es) Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20120219A1 (es) Inhibidores de beta-secretasa
PE20171342A1 (es) Compuestos y su uso como inhibidores de bace
PE20140161A1 (es) Compuesto biciclico
AR079334A1 (es) Derivados de oxazin amino
AR079061A1 (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
AR059516A1 (es) Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
PE20081467A1 (es) Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk)
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20091833A1 (es) Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
PE20091492A1 (es) Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed